Compare

Two terms, side by side

Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

Clinical & Trials

Investigator-Initiated Trial(IIT)

In one line

A clinical trial where an individual investigator (typically academic) — not the device or drug manufacturer — holds the regulatory sponsor role and is responsible for IRB, IDE/IND, and conduct.

Definition

An Investigator-Initiated Trial (IIT) is a clinical study in which an individual investigator (almost always an academic clinician) acts as the regulatory sponsor under 21 CFR 312 (drug IND) or 812 (device IDE), holding all sponsor obligations for protocol design, IRB/IEC submission, regulatory submissions, AE reporting, and study conduct. Industry support is typically limited to product supply and a financial grant under an Investigator-Initiated Research (IIR) agreement.

Why it matters

IITs are an important evidence-generation channel for new use cases, expanded populations, and combination studies that the manufacturer is unlikely to fund directly. Compliance landmines arise when industry inadvertently exerts study-design control, which can convert the study into a manufacturer-sponsored trial with full PMA/labeling implications.

Common pitfalls

•Industry sponsors providing too much protocol input — risks reclassification of the study as manufacturer-sponsored.
•Investigator-sponsors underestimating the regulatory burden they have assumed.

Sources

FDA — Investigator Responsibilities · FDA
21 CFR 312 — Investigational New Drug Application · eCFR
ClinicalTrials.gov · NIH

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.